Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:

Lianbio ADR (LIAN)

Lianbio ADR (LIAN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Help
Go To:
Why LianBio Stock Is Shooting Through the Roof This Week Motley Fool - Fri Oct 27, 2023

LianBio stock is seeing explosive gains, and it's one of this week's biggest winners.

LIAN : 0.3190 (-8.28%)
Why LianBio Stock Is Skyrocketing Today Motley Fool - Tue Oct 24, 2023

Investors are loving LianBio's new deal with Bristol Myers Squibb.

LIAN : 0.3190 (-8.28%)
BMY : 59.27 (+0.90%)
NANOBIOTIX and LianBio Announce First Patient Enrolled in Asia in Phase 3 NANORAY-312 Trial Evaluating NBTXR3 for the Treatment of Head and Neck Cancer Business Wire - Wed Sep 7, 2022

Regulatory News:

NBTX : 3.35 (-3.46%)
LIAN : 0.3190 (-8.28%)
LianBio Completes Enrollment in Pivotal Phase 3 EXPLORER-CN Trial of Mavacamten in Chinese Obstructive Hypertrophic Cardiomyopathy Patients Globe Newswire - Wed Aug 10, 2022

• Topline data expected mid-2023 • EXPLORER-CN trial, together with PK study conducted in healthy Chinese volunteers, expected to support registration of...

LIAN : 0.3190 (-8.28%)
LianBio to Participate in June Investor Events Globe Newswire - Thu Jun 2, 2022

SHANGHAI, China and PRINCETON, N.J., June 02, 2022 (GLOBE NEWSWIRE) -- LianBio (Nasdaq: LIAN), a biotechnology company dedicated to bringing innovative...

LIAN : 0.3190 (-8.28%)
LianBio Reports First Quarter 2022 Financial Results and Provides Corporate Update Globe Newswire - Thu May 12, 2022

LianBio’s partner, Bristol Myers Squibb, has received U.S. FDA approval of mavacamten for the treatment of patients with obstructive hypertrophic...

LIAN : 0.3190 (-8.28%)
U.S. Food and Drug Administration Approves Camzyos (mavacamten) for the Treatment of Adults with Symptomatic New York Heart Association Class II-III Obstructive Hypertrophic Cardiomyopathy (HCM) to Improve Functional Capacity and Symptoms Globe Newswire - Fri Apr 29, 2022

LianBio to Continue Development of Camzyos in China and Other Asian Territories...

LIAN : 0.3190 (-8.28%)
LianBio Announces Formation of Scientific Advisory Board Globe Newswire - Thu Apr 14, 2022

Scientific Advisory Board strengthens LianBio’s mission of bringing novel therapeutics to Greater China and Asia...

LIAN : 0.3190 (-8.28%)
LianBio’s Partner ReViral Enters into Acquisition Agreement with Pfizer Globe Newswire - Thu Apr 7, 2022

Acquisition builds on LianBio’s existing partnership with Pfizer to bring novel therapeutics to Greater China...

LIAN : 0.3190 (-8.28%)
PFE : 25.83 (+0.23%)
LianBio Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update Globe Newswire - Wed Mar 30, 2022

Phase 3 registrational trial of mavacamten in Chinese patients with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) ongoing Mavacamten granted...

LIAN : 0.3190 (-8.28%)

Barchart Exclusives

Will U.S. Bonds Keep Falling? Barchart - Thu Nov 28, 2:00PM CST
The U.S. Fed has cut the short-term Fed Funds Rate by 75 basis points since September 2024 and has told markets that more monetary policy easing is on the horizon. Meanwhile, longer-term rates continue to ignore the short-term rates as they climb to higher levels. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot